top five most promising drug

in todays advertiser.
An anti-cancer agent developed by BIONOMICS has been put in the international spot-light as a "promising" future drug. THOMSON PHARMA, a division of business information provider Thomson Reuters, named the vascular disrupting agent BNC-105 in the "TOP FIVE most promising drugs entering Phase 1 trials". BNC-105 being trialled for causing disruption to blood vessels in tumours and cancer cell death, is being tested on advanced cancer patients in melbourne and has US Food and Drug Administration approval.
Bionomics chief executive Deborah Rathjen said the Thomson Pharma review marked "important support".


FDA's approval
Top five most promising drug
Hold On Tight